Video

Dr. Graff Underscores Unmet Needs in ESR1-Mutated Breast Cancer

Stephanie L. Graff, MD, director of the Breast Program at the Sarah Cannon Cancer Institute of HCA Midwest Health and associate director of the Breast Cancer Research Program at Sarah Cannon Research Institute, discusses some unmet needs of patients with ESR1-mutated metastatic breast cancer.

Stephanie L. Graff, MD, director of the Breast Program at the Sarah Cannon Cancer Institute of HCA Midwest Health and associate director of the Breast Cancer Research Program at Sarah Cannon Research Institute, discusses some unmet needs of patients with ESR1-mutated metastatic breast cancer.

In the ER-positive space, patients with ESR1 mutations may not experience the same degree of benefit with fulvestrant (Faslodex) as other patients might, after they have progressed on either an aromatase inhibitor (AI) or an AI plus a CDK4/6 inhibitor, says Graff. Typically, this means that the patient will have a shorter duration of response to their second line of treatment or that they should be transitioned over to systemic chemotherapy, she explains.

Due to the increased toxicity associated with chemotherapy, Graff says that a main focus in this space is to keep patients on estrogen blockade for as long as possible. Bearing this in mind, further exploration into estrogen-based therapies for ESR1-mutated patients is needed, she concludes.

Related Videos
Timothy Gershon, MD, PhD
Jordan Hansford, MD
James J. Harding, MD, associate attending physician, Memorial Sloan Kettering Cancer Center
J. Bradley Elder, MD
Rimas V. Lukas, MD
Adam E. Singer, MD, PhD, Health Sciences Clinical Instructor, medicine, division lead, kidney cancer, Division of Hematology/Oncology, UCLA Health
Diane Reidy-Lagunes, MD, vice chair, Oncology Operations, Regional Care Network, Memorial Sloan Kettering Cancer Center
Shubham Pant, MD, MBBS
Kevin Kalinsky, MD, MS, professor, Department of Hematology and Medical Oncology, director, Division of Medical Oncology, Department of Hematology and Medical Oncology, Emory University School of Medicine; Louisa and Rand Glenn Family Chair in Breast Cancer Research, director, Glenn Family Breast Center, director, Breast Medical Oncology, Winship Cancer Institute of Emory University
Brett L. Ecker, MD